ClinicalTrials.gg
CompletedNCT05137002HALOUpdated Aug 1, 2023Results posted

A Study of CIN-107 in Patients With Uncontrolled Hypertension

A Phase 2 interventional study of CIN-107 and Placebo in Uncontrolled Hypertension, sponsored by CinCor Pharma, Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by CinCor Pharma, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
7th of 18
249 · median 197
Started
2021
with 3 others
Phase 2
5 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
2 of 18
CinCor Pharma, Inc.

Among the 18 studies testing baxdrostat in Hypertension, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 2nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of multiple dose strengths of baxdrostat (also called CIN-107) in the treatment of patients with uncontrolled hypertension. The primary objective was to demonstrate that treatment with baxdrostat for 8 weeks would lower the systolic blood pressure (SBP) in patients who were hypertensive despite taking one or two anti-hypertensive medications.

Participants were assigned to take placebo or baxdrostat once per day for 8 weeks while they continued taking the regular anti-hypertensive medications. At the end of the 8-week period, qualified patients could participate in Part II of the study and receive 2 mg baxdrostat for 4 weeks while they discontinued taking the background anti-hypertensive medication.

03

Conditions studied

  • Uncontrolled Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is on a stable regimen of background antihypertensive agent(s) for at least 8 weeks and would be considered a candidate for an additional antihypertensive agent at the time of screening ;
  • Has a mean seated systolic blood pressure (SBP) ≥ 140 mmHg or ≥ 130 mmHg if diabetic;
  • Demonstrates ability to be adherent to the study drug and their anti-hypertensive medication during a run-in period
  • If taking an SGLT2 inhibitor, the regimen must be stable for at least 8 weeks prior to randomization; and
  • Agrees to comply with the and reproduction restrictions of the study;

Exclusion criteria

Exclusion Criteria:

  • Has a mean seated systolic blood pressure (SBP) ≥180 mmHG;
  • Has a (BMI) >50 kg/m2;
  • Is using alpha or beta blockers for any primary indication other than systemic hypertension (eg, migraine headache);
  • Is not willing or not able to discontinue an MRA or potassium sparing diuretic as part of an existing antihypertensive regimen;
  • Has documented estimated \<30 mL/min/1.73m2;
  • Has known and documented stage III or IV chronic heart failure;
  • Has had a stroke, , hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before screening;
  • Major cardiac surgery within 6 months before Screening;
  • Has chronic permanent atrial fibrillation;
  • Has uncontrolled diabetes with >10% at Screening;
  • Has planned dialysis or kidney transplantation planned during the course of the study;
  • Prior solid organ transplant and/or cell transplants;
  • Sodium \<130 mEq/L;
  • Potassium \<3.5 mEq/L;
  • Potassium >5 mEq/L;
  • White blood cell count >15 × E9/L or \<1 × E9/L at Screening;
  • Is positive for antibody, virus RNA, or surface antigen;
  • Has typical consumption of ≥14 alcoholic drinks weekly;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    CIN-107 0.5 mg

    Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks

    Drug: CIN-107

  • Experimental
    CIN-107 1 mg

    Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks

    Drug: CIN-107

  • Experimental
    CIN-107 2 mg

    Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient may remain on CIN-107 (2 mg) and discontinue their background antihypertensive agent(s) for 4 weeks or withdraw study participation depending on BP control

    Drug: CIN-107

  • Placebo comparator
    Placebo

    Remain on background anti-hypersensitive regimen for 8 weeks. After 8 weeks, patient will receive the highest dose of CIN-107 (2mg) and discontinue their background antihypertensive agent(s) for 4 weeks

    Drug: Placebo

Interventions

  • CIN-107 tablets by mouth once daily

    Also known as: Baxdrostat

  • DrugPlacebo

    Placebo tablets by mouth once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Seated Systolic BP (SBP)

    The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1).

    Time frame: 8 weeks

Secondary outcomes

  1. Change From Baseline in Mean Seated Diastolic BP (DBP)

    The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

    Time frame: 8 weeks

  2. Change From Baseline in 24-hour Urine Aldosterone

    The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)

    Time frame: 8 weeks

  3. Change From Baseline in 24-hour Serum Aldosterone

    The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)

    Time frame: 8 weeks

  4. Percentage of Patients Achieving a Mean Seated SBP <130 mmHg

    The percentage of patients achieving a mean seated SBP \<130 mmHg ("responders") with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8)

    Time frame: 8 weeks

  5. Change From Baseline in 24-hour Urine Renin

    The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

    Time frame: 8 weeks

  6. Change From Baseline in 24-hour Serum Renin

    The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

    Time frame: 8 weeks

07

Results

Posted Aug 1, 2023

Participant flow

Part I (8 Weeks)
Participant flow — Part I (8 Weeks)
MilestonePlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgPart II - CIN-107 2mg
Started646362600
Completed605558540
Not completed48460
Part II (4 Weeks)
Participant flow — Part II (4 Weeks)
MilestonePlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgPart II - CIN-107 2mg
Started0000213
Completed0000201
Not completed000012

Outcome measures

PrimaryChange From Baseline in Mean Seated Systolic BP (SBP)

The primary efficacy endpoint was the change from baseline in mean seated SBP after 8 weeks of treatment in patients with uncontrolled HTN (Part 1).

Time frame:
8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Seated Systolic BP (SBP)
mmHgPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Change From Baseline in Mean Seated Systolic BP (SBP)-16.6 ± 1.58-17.0 ± 1.63-16.0 ± 1.62-19.8 ± 1.67
SecondaryChange From Baseline in Mean Seated Diastolic BP (DBP)

The change from baseline in mean seated DBP with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

Time frame:
8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Seated Diastolic BP (DBP)
mmHgPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Change From Baseline in Mean Seated Diastolic BP (DBP)-5.9 ± 1.17-5.8 ± 1.20-5.0 ± 1.19-5.4 ± 1.23
SecondaryChange From Baseline in 24-hour Urine Aldosterone

The change from baseline in 24-hour urine aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)

Time frame:
8 weeks
Reported as:
Least squares mean · ng/g
Change From Baseline in 24-hour Urine Aldosterone
ng/gPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Change From Baseline in 24-hour Urine Aldosterone-19.90 ± 29.183-114.16 ± 31.305-140.45 ± 29.999-121.64 ± 30.760
SecondaryChange From Baseline in 24-hour Serum Aldosterone

The change from baseline in 24-hour serum aldosterone levels with CIN 107 compared to placebo after 8 weeks of treatment (Part 1)

Time frame:
8 weeks
Reported as:
Least squares mean · ng/dL
Change From Baseline in 24-hour Serum Aldosterone
ng/dLPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Change From Baseline in 24-hour Serum Aldosterone-0.70 ± 0.490-2.76 ± 0.493-2.95 ± 0.508-2.92 ± 0.515
SecondaryPercentage of Patients Achieving a Mean Seated SBP <130 mmHg

The percentage of patients achieving a mean seated SBP \<130 mmHg ("responders") with CIN-107 compared to placebo after 8 weeks of treatment (Part 1; Weeks 1 to 8)

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Percentage of Patients Achieving a Mean Seated SBP <130 mmHg
ParticipantsPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Percentage of Patients Achieving a Mean Seated SBP <130 mmHg36363343
SecondaryChange From Baseline in 24-hour Urine Renin

The change from baseline in 24-hour urine renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

Time frame:
8 weeks
Reported as:
Least squares mean · ng/day
Change From Baseline in 24-hour Urine Renin
ng/dayPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Change From Baseline in 24-hour Urine Renin-20.08 ± 16.584-6.54 ± 15.739-5.74 ± 10.7034.11 ± 17.930
SecondaryChange From Baseline in 24-hour Serum Renin

The change from baseline in 24-hour serum renin levels with CIN-107 compared to placebo after 8 weeks of treatment (Part 1)

Time frame:
8 weeks
Reported as:
Least squares mean · ng/L
Change From Baseline in 24-hour Serum Renin
ng/LPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mg
Change From Baseline in 24-hour Serum Renin92.902 ± 144.396963.565 ± 195.049588.041 ± 91.2996-140.961 ± 151.5431

Adverse events

Collected over Part I - AEs during the 8-week treatment period Part II - AEs during the following 4-week treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/64 (0%)0/64 (0%)5/64 (7.8%)
CIN-107 0.5 mg0/63 (0%)0/63 (0%)8/63 (12.7%)
CIN-107 1 mg0/62 (0%)1/62 (1.6%)6/62 (9.7%)
CIN-107 2 mg1/60 (1.7%)1/60 (1.7%)3/60 (5%)
Part II - CIN-107 2 mg0/213 (0%)3/213 (1.4%)6/213 (2.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgPart II - CIN-107 2 mg
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/640/630/621/600/213
Acute myocardial infarctionCardiac disorders0/640/631/620/600/213
HyperglycaemiaMetabolism and nutrition disorders0/640/630/620/601/213
DizzinessNervous system disorders0/640/630/620/601/213
Hypertensive urgencyVascular disorders0/640/630/620/601/213
BradycardiaCardiac disorders0/640/630/620/601/213
Most frequent other events
Most frequent other events
EventPlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgPart II - CIN-107 2 mg
HyperkalaemiaMetabolism and nutrition disorders3/640/635/623/606/213
SARS-CoV-2 test positiveInvestigations2/644/631/620/600/213
DiarrhoeaGastrointestinal disorders1/644/630/620/600/213

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
<=18 years00000
Between 18 and 65 years40373741155
>=65 years2426251994
Age, Continuous
Age, Continuous(years)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
Mean60.5 ± 10.6159.9 ± 10.8561.2 ± 10.6959.2 ± 11.8860.2 ± 10.96
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
Female37283730132
Male27352530117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
Hispanic or Latino31392835133
Not Hispanic or Latino33243425116
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
American Indian or Alaska Native00000
Asian11226
Native Hawaiian or Other Pacific Islander00000
Black or African American1714151460
White46484344181
More than one race00000
Unknown or Not Reported00202
Region of Enrollment
Region of Enrollment(participants)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
United States64636260249
Seated SBP
Seated SBP(mmHg)PlaceboCIN-107 0.5 mgCIN-107 1 mgCIN-107 2 mgTotal
Mean147.9 ± 9.33146.3 ± 8.60147.0 ± 9.07146.3 ± 7.83146.9 ± 8.71
08

Study locations

63 sites
  • CinCor Site 27
    Saraland, Alabama 36571, United States
  • CinCor Site 35
    Tucson, Arizona 85712, United States
  • CinCor Site 69
    Encinitas, California 92024, United States
  • CinCor Site 6
    Lincoln, California 95648, United States
  • CinCor Site 20
    Los Angeles, California 90057, United States
  • CinCor Site 70
    Lynwood, California 90262, United States
  • CinCor Site 36
    Northridge, California 91324, United States
  • CinCor Site 29
    Oceanside, California 92049, United States
  • CinCor Site 46
    Panorama City, California 91402, United States
  • CinCor Site 47
    San Dimas, California 91773, United States
  • CinCor Site 49
    Santa Ana, California 92705, United States
  • CinCor Site 52
    West Hills, California 91307, United States
  • CinCor Site 57
    Denver, Colorado 80209, United States
  • CinCor Site 31
    Waterbury, Connecticut 06708, United States
  • CinCor Site 18
    Clearwater, Florida 33765, United States
  • CinCor Site 41
    Cooper City, Florida 33024, United States
  • CinCor Site 28
    Homestead, Florida 33166, United States
  • CinCor Site 9
    Jupiter, Florida 33458, United States
  • CinCor Site 1
    Lake Worth, Florida 33460, United States
  • CinCor Site 12
    Miami, Florida 33032, United States
  • CinCor Site 54
    Miami, Florida 33106, United States
  • CinCor Site 13
    Miami, Florida 33155, United States
  • CinCor Site 17
    Miami, Florida 33183, United States
  • CinCor Site 16
    Tampa, Florida 33606, United States
  • CinCor Site 34
    Winter Haven, Florida 33880, United States
  • CinCor Site 14
    Buford, Georgia 30519, United States
  • CinCor Site 33
    Addison, Illinois 60101, United States
  • CinCor Site 40
    Chicago, Illinois 60607, United States
  • CinCor Site 42
    Gurnee, Illinois 60031, United States
  • CinCor Site 50
    Morton, Illinois 61550, United States
  • CinCor Site 72
    Brownsburg, Indiana 46112, United States
  • CinCor Site 63
    West Des Moines, Iowa 50266, United States
  • CinCor Site 7
    Lexington, Kentucky 40503, United States
  • CinCor Site 21
    Louisville, Kentucky 40213, United States
  • CinCor Site 30
    Marrero, Louisiana 70072, United States
  • CinCor Site 59
    Metairie, Louisiana 70004, United States
  • CinCor Site 19
    New Orleans, Louisiana 70112, United States
  • CinCor Site 25
    Shreveport, Louisiana 71106, United States
  • CinCor Site 38
    Elkridge, Maryland 21043, United States
  • CinCor Site 38
    Elkridge, Maryland 21075, United States
  • CinCor Site 22
    Troy, Michigan 48085, United States
  • CinCor Site 64
    Olive Branch, Mississippi 38654, United States
  • CinCor Site 11
    Brooklyn, New York 11201, United States
  • CinCor Site 65
    Staten Island, New York 10305, United States
  • CinCor Site 15
    Cincinnati, Ohio 45221, United States
  • CinCor Site 24
    Columbus, Ohio 43213, United States
  • CinCor Site 4
    Dayton, Ohio 45377, United States
  • CinCor Site 43
    Oklahoma City, Oklahoma 73119, United States
  • CinCor Site 60
    Chattanooga, Tennessee 37401, United States
  • CinCor Site 48
    Austin, Texas 78705, United States
  • CinCor Site 32
    Carrollton, Texas 75006, United States
  • CinCor Site 68
    Dallas, Texas 75234, United States
  • CinCor Site 61
    Georgetown, Texas 78613, United States
  • CinCor Site 55
    Houston, Texas 77036, United States
  • CinCor Site 3
    Houston, Texas 77040, United States
  • CinCor Site 58
    Katy, Texas 77450, United States
  • CinCor Site 62
    Lampasas, Texas 76550, United States
  • CinCor Site 26
    McAllen, Texas 78501, United States
  • CinCor Site 53
    San Antonio, Texas 78209, United States
  • CinCor Site 10
    Sugar Land, Texas 77479, United States
  • CinCor Site 45
    Salt Lake City, Utah 84102, United States
  • CinCor Site 2
    Manassas, Virginia 20108, United States
  • CinCor Site 5
    Norfolk, Virginia 23510, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Sep 2022, 9 months.

Results were first posted in Aug 2023, 10 months after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 9 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Nov 30, 2021
StartActual
Dec 7, 2021
Primary completionActual
Sep 13, 2022
CompletionActual
Oct 10, 2022
Results first posted
Aug 1, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05137002
Responsible party
Sponsor
First posted
Nov 30, 2021
Start date
Dec 7, 2021
Primary completion
Sep 13, 2022
Completion
Oct 10, 2022
Results posted
Aug 1, 2023
Last update
Aug 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion